Home Articles List Article Information
Iranian Journal of Pharmaceutical Research
Journal Archive
Volume Volume 18 (2019)
Volume Volume 17 (2018)
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., Velayati, A. (2016). Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 15(1), 247-252. doi: 10.22037/ijpr.2016.1825
Majid Marjani; Parvaneh Baghaei; Mehdi Kazempour Dizaji; Pegah Gorji Bayani; Fanak Fahimi; Payam Tabarsi; Ali Akbar Velayati. "Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial". Iranian Journal of Pharmaceutical Research, 15, 1, 2016, 247-252. doi: 10.22037/ijpr.2016.1825
Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., Velayati, A. (2016). 'Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial', Iranian Journal of Pharmaceutical Research, 15(1), pp. 247-252. doi: 10.22037/ijpr.2016.1825
Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., Velayati, A. Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 2016; 15(1): 247-252. doi: 10.22037/ijpr.2016.1825

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Article 23, Volume 15, Issue 1, Winter 2016, Page 247-252  XML PDF (2.05 MB)
Document Type: Research article
DOI: 10.22037/ijpr.2016.1825
Authors
Majid Marjani1; Parvaneh Baghaei email 1; Mehdi Kazempour Dizaji2; Pegah Gorji Bayani1; Fanak Fahimi3; Payam Tabarsi4; Ali Akbar Velayati3
1Clinical Tuberculosis and Epidemiology Research Center
2Mycobacteriology Research Center
3Chronic Respiratory Diseases Research Center
4Clinical Tuberculosis and Epidemiology Research Cente
Abstract
Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment.
Trial registration: ANZCTR registration ID: ACTRN12610000621011.
Keywords
Tuberculosis; adverse effects; Silymarin; drug induced hepatitis
Main Subjects
Pharmacotherapy (Clinical Pharmacy); toxicology and Pharmacology
Statistics
Article View: 7,938
PDF Download: 25,812